Listed

Mesa Laboratories Inc: Form 10-Q for the period ended Sep 30, 2013

Filed with the SEC on Nov 5, 2013 and accepted by EDGAR at Nov 5, 2013, 15:02 ET.

Share

Management's discussion and analysis

As filed, 22,414 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Forward Looking Statements

This report contains information that may constitute “forward-looking statements.” Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to those described in Part II, “Item 1A. Risk Factors” and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2013, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.

General Discussion

We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into two divisions across four physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries. Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. We follow a philosophy of manufacturing a high quality product and providing a high level of on-going service for those products.

Our revenues come from two main sources — products sales, and parts and services. Product sales are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products, and acquisitions. Biological indicator products are disposable and are used on a routine basis for quality control, thus product sales are less sensitive to general economic conditions. Instrument products have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Parts and service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products. We typically evaluate costs and pricing annually. Our policy is to price our products competitively and, where possible, we try to pass along cost increases in order to maintain our margins.

Gross profit is affected by our product mix, manufacturing efficiencies and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margins for some of the products have improved. There are, however, differences in gross margins between different product lines, and ultimately the mix of sales may continue to impact our overall gross margin.

Selling expense is driven primarily by labor costs, including salaries and commissions. Accordingly, it may vary with sales levels. Labor costs and amortization of intangible assets drive 70-80% of general and administrative expense. Research and development expense is predominantly comprised of labor costs and third party consultants.

In May 2012, we completed the Bios Acquisition by acquiring specific assets and assuming certain liabilities of Bios, a New Jersey corporation, for $16,660,000 and potential contingent consideration based on revenue growth over a three year earn-out period.

In July 2013, we completed a business combination by entering into an asset purchase agreement with ST Acquisitions pursuant to which we acquired essentially all of the assets of ST Acquisitions’ business involving the design, manufacturing, sale and service of its SureTorque line of bottle cap torque testing instrumentation. The purchase price for the acquired assets was $1,821,000, consisting of a cash payment of $1,721,000 at closing and a $100,000 holdback amount that is expected to be settled on July 1, 2014.

In August 2013, we entered into an agreement whereby we sold our NuSonics product line for $661,000, which resulted in a pre-tax gain of $468,000.

General Trends and Outlook

Our strategic objectives include growth both organically and through further acquisitions. During the year ended March 31, 2013, we continued to build our infrastructure to prepare for future growth, including the addition of key personnel to our operations, research and development, and finance teams. As needed, we intend to continue to strengthen our infrastructure during the year ending March 31, 2014, including our information systems. We expect Sarbanes-Oxley (“SOX”) compliance costs to remain relatively flat during the year ending March 31, 2014, as we maintain our internal control structure while simultaneously making efficient and effective improvements.

The markets for our biological indicators remain strong, as the disposable nature of these products makes them less sensitive to general economic conditions. The worldwide market for biological indicators is growing, as more countries focus on verifying the effectiveness of sterilization processes. Recent general economic conditions however have slowed the organic growth of our instruments business, due to the discretionary nature of these products. Additionally, uncertainty about global economic conditions may cause businesses to postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Worldwide and regional economic conditions could also reduce the demand for our products and services, as our customers reduce or delay capital equipment and other types of purchases. Demand for our instruments products, however, is still strong and we strive to maintain or grow revenue going forward.

We are working on several research and development projects that, if completed, may result in new products for both existing customers and in new markets. We are hopeful that both our Biological Indicators and Instruments Divisions will have new products available for sale in the coming year.

Results of Operations

The following table sets forth, for the periods indicated, condensed statements of income data. The table and the discussion below should be read in conjunction with the accompanying condensed financial statements and the notes thereto appearing elsewhere in this report (in thousands, except percent data):

Three months ended September 30, 2013 2012 Change Percent Change
Revenues $12,676 $11,706 $970 8%
Cost of revenues 5,076 4,458 618 14%
Gross profit $7,600 $7,248 $352 5%
Gross margin 60% 62% (2)%
Operating expenses
Selling $1,419 $1,072 $347 32%
General and administrative 3,136 2,169 967 45%
Research and development 530 519 11 2%
$5,085 $3,760 $1,325 35%
Net income $1,932 $2,248 $(316) (14)%
Net profit margin 15% 19% (4)%
Six months ended September 30, 2013 2012 Change Percent Change
Revenues $23,894 $22,266 $1,628 7%
Cost of revenues 9,497 8,562 935 11%
Gross profit $14,397 $13,704 $693 5%
Gross margin 60% 62% (2)%
Operating expenses
Selling $2,502 $2,074 $428 21%
General and administrative 5,222 4,023 1,199 30%
Research and development 1,115 899 216 24%
$8,839 $6,996 $1,843 26%
Net income $3,792 $4,348 $(556) (13)%
Net profit margin 16% 20% (4)%

12

Revenues

The following table summarizes our revenues by source (in thousands, except percent data):

Three months ended September 30, 2013 2012 Change Percent Change
Biological Indicators $6,010 $5,320 $690 13%
Instruments 6,666 6,386 280 4%
Total $12,676 $11,706 $970 8%
Six months ended September 30, 2013 2012 Change Percent Change
Biological Indicators $10,864 $10,438 $426 4%
Instruments 13,030 11,828 1,202 10%
Total $23,894 $22,266 $1,628 7%

Three and six months ended September 30, 2013 versus September 30, 2012

Biological Indicators revenues for the three and six months ended September 30, 2013 increased as compared to the prior year as a result of continued organic growth, achieved through existing customers and expansion into new markets. In addition, Biological Indicators revenues for the three months ended September 30, 2013 also increased as compared to the prior year due to the fulfillment of backlog from the previous quarter end which resulted from the requirement to replace three product batches that had longer than expected incubation times. Our efforts to quickly manufacture and replace these product batches during the three months ended June 30, 2013 decreased product available to fulfill new orders, which resulted in an increase from our typical backlog at the end of the prior quarter. We were successful in our efforts to fulfill substantially all of this backlog during the three months ended September 30, 2013.

Instruments revenues for the three and six months ended September 30, 2013 increased as compared to the prior year primarily from organic growth in our Bios product line and the acquisition of the SureTorque product line, while other Instruments product lines remained relatively unchanged. The increase in Instruments revenues for the six months ended September 30, 2013 as compared to the prior year was also impacted by the timing of the Bios Acquisition in the prior year.

Gross Profit

The following summarizes our gross profit by segment (in thousands, except percent data):

Three months ended September 30, 2013 2012 Change Percent Change
Biological Indicators $3,482 $3,063 $419 14%
Gross profit margin 58% 58% 0%
Instruments 4,118 4,185 (67) (2)%
Gross profit margin 62% 66% (4)%
Total $7,600 $7,248 $352 5%
Gross profit margin 60% 62% (2)%

13

Six months ended September 30, 2013 2012 Change Percent Change
Biological Indicators $6,043 $5,956 $87 1%
Gross profit margin 56% 57% (1)%
Instruments 8,354 7,748 606 8%
Gross profit margin 64% 66% (2)%
Total $14,397 $13,704 $693 5%
Gross profit margin 60% 62% (2)%

Three and six months ended September 30, 2013 versus September 30, 2012

Biological Indicators gross profit margin percentage for the three months ended September 30, 2013 remained flat as compared to the prior year. Biological Indicators gross profit margin percentage for the six months ended September 30, 2013 decreased as compared to the prior year as a result of the cost of replacement product associated with the three product batches that had longer than expected incubation times (as discussed above in Revenues).

Instruments gross profit margin percentage for the three months ended September 30, 2013 decreased as compared to the prior year primarily as a result of the application of purchase accounting associated with the Suretorque Acquisition. Instruments gross profit margin percentage for the six months ended September 30, 2103 decreased as compared to the prior year primarily as a result of the application of purchase accounting associated with the Suretorque Acquisition partially offset by the timing of the Bios Acquisition in the prior year.

Operating Expenses

Operating expenses for the three and six months ended September 30, 2013 increased (decreased) as compared to the prior year as follows (in thousands):

Increase (Decrease) Three months ended September 30, 2013 Six months ended September 30, 2013
Selling $347 $428
General and administrative
Amortization (54) (23)
Personnel costs (64) 78
Taxes and Fees 1,071 1,053
Other, net 14 91
967 1,199
Research and development 11 216
Operating expenses $1,325 $1,843

Three and six months ended September 30, 2013 versus September 30, 2012

*Selling—*Selling expenses for the three months ended September 30, 2103 increased as compared to the prior year primarily due to the Suretorque Acquisition, along with negligible increases from other product lines. Selling expenses for the six months ended September 30, 2013 increased primarily due to the Suretorque and Bios acquisitions.

*General and administrative —*General and administrative expenses for the three and six months ended September 30, 2103 increased as compared to the prior year primarily as a result of the recording of a $1,106,000 accrual associated with not properly collecting and remitting sales tax in states in which we most likely had established nexus during prior periods. The increase in general and administrative expenses for the six months ended September 30, 2103 as compared to prior year was also impacted by the timing of the Bios acquisition in the prior year.

Research and development— Research and development expenses for the three months ended September 30, 2013 was relatively flat as compared to the prior year. Research and development expenses for the six months ended September 30, 2013 increased as compared to the prior year as a result of the Bios Acquisition and timing of external research and development consulting costs, as we continue our commitment to research and development.

Net Income

Other income (expense) for the three and six months ended September 30, 2013 increased as compared to the prior year as a result of the Nusonics Disposal. Our estimated effective income tax rate increased to 36.3% for the three and six months ended September 30, 2013, from 34.9% and 34.5% for the three and six months ended September 30, 2012, respectively. We anticipate that on a go forward basis, our effective tax rate will approximate our current rate of 36.3%. Otherwise, net income varied with the changes in revenue, gross profit and operating expenses.

Liquidity and Capital Resources

Our sources of liquidity may include cash generated from operations, working capital, capacity under our Credit Facility and potential equity and debt offerings. We believe that cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources include quarterly dividends to stockholders, payment of debt obligations, long-term capital equipment expenditures and potential acquisitions.

Working capital is the amount by which current assets exceed current liabilities. We had working capital of $13,914,000 and $14,793,000 at September 30, 2013 and March 31, 2013, respectively. The decrease in working capital is primarily due to the use of cash for the repayment of long-term debt, the timing of the collection of accounts receivable and the recording of a $1,106,000 accrual associated with not properly collecting and remitting sales tax in states in which we most likely had established nexus during prior periods.

In February 2012, we entered into the Credit Facility, which is comprised of a three year agreement for a $20,000,000 revolving line of credit and up to $1,000,000 of letters of credit. Funds from the Credit Facility may be used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures. In May 2012, we borrowed $11,000,000 against the Line of Credit to partially finance the Bios Acquisition. There were no amounts outstanding under the Line of Credit at September 30, 2013 and we had unused capacity of $20,000,000.

We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume third party debt or incur other long-term obligations. We believe that we have the option to utilize both equity and debt instruments as vehicles for the long-term financing of our investment activities and acquisitions.

On November 7, 2005, our Board of Directors authorized a program to repurchase up to 300,000 shares of our outstanding common stock. Under the plan, the shares may be purchased from time to time in the open market at prevailing prices or in negotiated transactions off the market. Shares purchased will be canceled and repurchases will be made with existing cash reserves. We do not maintain a set policy or schedule for our buyback program. We have purchased 161,631 shares of common stock under this program from inception through September 30, 2013.

We have been paying regular quarterly dividends since 2003. Dividends per share paid by quarter were as follows:

Year ending March 31, 2014 2013
First quarter $0.14 $0.13
Second quarter 0.14 0.13
Third quarter — 0.14
Fourth quarter — 0.14

In October 2013, our Board of Directors declared a quarterly cash dividend of $0.15 per share of common stock, payable on December 16, 2013, to stockholders of record at the close of business on November 29, 2013.

Cash Flows

Our cash flows from operating, investing and financing activities were as follows (in thousands):

Six months ended September 30, 2013 2012
Net cash provided by operating activities $5,579 $4,926
Net cash used in investing activities (1,831) (17,030)
Net cash (used in) provided by financing activities (4,330) 7,685

Net cash provided by operating activities for the six months ended September 30, 2013 increased primarily due to increases in revenues and positive results from efforts to collect long-outstanding receivables partially offset by higher expenses associated with the timing of the Bios Acquisition and the timing of other working capital expenditures.

Net cash used in investing activities for the six months ended September 30, 2013 resulted from the $1,721,000 Suretorque Acquisition and the purchase of $771,000 of property, plant and equipment partially offset by the proceeds from the NuSonics Disposal. Net cash used in investing activities for the six months ended September 30, 2012 resulted from the $16,660,000 Bios Acquisition and the purchase of $370,000 of property, plant and equipment

Net cash used in financing activities for the six months ended September 30, 2013 resulted from the repayment of debt of $4,000,000 and the payment of dividends of $952,000, partially offset by proceeds from the exercise of stock options of $637,000. Net cash provided by financing activities for the six months ended September 30, 2012 resulted from borrowings under our Line of Credit of $11,000,000 and proceeds from the exercise of stock options of $613,000, partially offset by the repayment of debt of $3,000,000 and the payment of dividends of $871,000.

At September 30, 2013, we had contractual obligations for open purchase orders of approximately $1,300,000 for routine purchases of supplies and inventory, which would be payable in less than one year. As part of our Bios Acquisition, the Bios Agreement includes a provision for contingent consideration based on revenue growth over a three year earn-out period. The contingent consideration arrangement requires us to pay Bios if cumulative revenues from the acquisition for the three years subsequent to the acquisition exceed $22,127,000. The potential undiscounted future payment that we could be required to make ranges from $0 to $6,710,000.

In July 2013, we completed the SureTorque Acquisition for a purchase price of $1,821,000, consisting of a cash payment of $1,721,000 at closing and a $100,000 holdback amount that is expected to be settled on July 1, 2014.

Critical Accounting Estimates

Our condensed financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2013 in the Critical Accounting Policies and Estimates section of “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Controls and procedures

As filed, 2,725 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to reasonably ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of September 30, 2013. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective at September 30, 2013.

Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Management evaluated the effectiveness of our internal control over financial reporting based on the framework in “Internal Control — Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of September 30, 2013. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at September 30, 2013.

Changes in Internal Control Over Financial Reporting

There were no significant changes in our internal control over financial reporting that occurred during the six months ended September 30, 2013, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Risk factors

As filed, 1,901 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2013, under the heading “Part I — Item 1A. Risk Factors.” There have been no material changes to those risk factors other than the following:

Catastrophic events or environmental conditions may disrupt our business.

A disruption or failure of our systems or operations because of a major weather event, cyber-attack, terrorist attack, or other catastrophic event could cause delays in completing sales, providing services or performing other mission-critical functions. A catastrophic event that results in the destruction or disruption of any of our critical business or IT systems could harm our ability to conduct normal business operations. Abrupt political change, terrorist activity, and armed conflict pose a risk of general economic disruption in affected countries, which may increase our operating costs or adversely affect our revenues. These conditions also may add uncertainty to the timing and budget for purchase/investment decisions by our customers, and may result in supply chain disruptions for hardware manufacturers, either of which may adversely affect our revenue. The long-term effects of climate change on the global economy in general or the Industrial Instruments industry in particular are unclear. Environmental regulations or changes in the supply, demand or available sources of energy may affect the availability or cost of goods and services, including natural resources, necessary to run our business. Changes in weather where we operate may increase the costs of powering and maintaining the equipment we need to produce our product lines.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-07-01 to 2013-09-30$12.7mus-gaap:SalesRevenueNet
Revenue6 months2013-04-01 to 2013-09-30$23.9mus-gaap:SalesRevenueNet
Gross profit3 months2013-07-01 to 2013-09-30$7.6mus-gaap:GrossProfit
Gross profit6 months2013-04-01 to 2013-09-30$14.4mus-gaap:GrossProfit
Research and development3 months2013-07-01 to 2013-09-30$530.0kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2013-04-01 to 2013-09-30$1.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2013-07-01 to 2013-09-30$2.5mus-gaap:OperatingIncomeLoss
Operating income6 months2013-04-01 to 2013-09-30$5.6mus-gaap:OperatingIncomeLoss
Income tax3 months2013-07-01 to 2013-09-30$1.0mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2013-04-01 to 2013-09-30$2.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2013-07-01 to 2013-09-30$1.9mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income6 months2013-04-01 to 2013-09-30$3.8mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2013-07-01 to 2013-09-30$0.54us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2013-04-01 to 2013-09-30$1.06us-gaap:EarningsPerShareDiluted
Basic EPS3 months2013-07-01 to 2013-09-30$0.57us-gaap:EarningsPerShareBasic
Basic EPS6 months2013-04-01 to 2013-09-30$1.11us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2013-07-01 to 2013-09-303,592,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2013-04-01 to 2013-09-303,568,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2013-04-01 to 2013-09-30$5.6mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Dividends paid6 months2013-04-01 to 2013-09-30$952.0kus-gaap:PaymentsOfDividendsCommonStock
Share repurchases6 months2013-04-01 to 2013-09-30$15.0kus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2013-09-30$3.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-09-30$18.6mus-gaap:AssetsCurrent
Total assetsAt period end2013-09-30$65.8mus-gaap:Assets
Current liabilitiesAt period end2013-09-30$4.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-09-30$9.2mus-gaap:Liabilities
Shareholders' equityAt period end2013-09-30$56.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-13-081104. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.